SLU-PP-322 vs AOD-9604: Exercise Mimetic vs Fat-Targeting Peptide — What Metabolic Researchers Are Studying in 2026

SLU-PP-322 and AOD-9604 represent two distinct research strategies in the metabolic peptide space — one targeting nuclear receptor pathways to simulate exercise adaptation, the other derived from growth hormone to selectively influence fat metabolism. As interest in metabolic peptide research accelerates through 2026, laboratories are increasingly asking a pointed question: which compound addresses which biological mechanism, and can studying them together reveal complementary insights into obesity-related pathways?

This guide breaks down the core mechanistic differences between SLU-PP-322 and AOD-9604, examines what preclinical studies have explored in each area, and outlines the key distinctions that metabolic researchers should understand when designing experiments around these two compounds.

Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

SLU — PP — 332 — 5MG

SLU-PP-332 - 5MG — Research-Grade Reference Material SLU-PP-332 - 5MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…

$75.00 ($56.25 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

Frequently Asked Questions

What is SLU-PP-322 and how does it work?

SLU-PP-322 is a synthetic small molecule agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ). In preclinical models, it has been studied for its ability to activate gene expression programs associated with endurance exercise, including mitochondrial biogenesis and oxidative metabolism — without physical exertion. This is why it is referred to as an “exercise mimetic” in research literature.

What is AOD-9604 and how does it differ from SLU-PP-322?

AOD-9604 is a modified fragment of the C-terminus of human growth hormone (hGH176-191). Unlike SLU-PP-322, which activates nuclear transcription programs, AOD-9604 has been studied for its ability to stimulate lipolysis and inhibit lipogenesis through mechanisms that do not appear to involve IGF-1 pathways. It targets fat tissue more directly rather than broadly mimicking exercise adaptation.

Are SLU-PP-322 and AOD-9604 approved for human use?

Neither SLU-PP-322 nor AOD-9604 is approved for human therapeutic use in the United States. Both are classified as research compounds intended strictly for laboratory investigation. Researchers should review current regulatory guidance before initiating any study involving these peptides.

What metabolic pathways does SLU-PP-322 target?

SLU-PP-322 primarily targets ERR (estrogen-related receptor) transcription factors, which regulate mitochondrial function, fatty acid oxidation, and energy expenditure. Studies in rodent models have suggested it can increase exercise capacity and promote oxidative fiber transformation in skeletal muscle without requiring physical activity.

What does AOD-9604 research focus on?

AOD-9604 research has concentrated on adipose tissue metabolism — specifically lipolysis stimulation and inhibition of new fat cell formation (lipogenesis). Early clinical trials explored its potential in obesity research, though no approved formulation has resulted. Preclinical data also suggest possible cartilage and tissue repair properties.

Can SLU-PP-322 and AOD-9604 be studied together?

Some researchers have theorized that because SLU-PP-322 targets transcriptional exercise adaptation and AOD-9604 targets lipolytic fat breakdown, their mechanisms could be studied in parallel in metabolic models. However, no published combined studies currently exist, and any such research design would require careful independent characterization of each compound’s effects.

Where can researchers source SLU-PP-322 and AOD-9604 for laboratory use?

Both compounds are available as research-grade peptides from qualified suppliers. Researchers should verify purity certificates, third-party testing documentation, and confirm the materials are intended for laboratory use only before procurement.

Two Different Mechanisms, One Research Goal: Understanding Metabolic Diversity

The growing interest in metabolic peptide research has pushed laboratories to look beyond GLP-1 receptor agonists and explore compounds that engage with fat metabolism at different levels of biology. As GLP peptide research expands across multiple receptor classes, compounds like SLU-PP-322 and AOD-9604 attract attention for offering mechanistically distinct entry points into metabolic dysfunction.

🎫 First order? Save 25% with code WELCOMEHOME at checkout

Research compounds discussed in this guide

SLU — PP — 332 — 5MG

$75.00 ($56.25 With Your 1st Order)

View Research Data

For research use only · 3rd-party tested · Free 2-5 day US shipping

SLU-PP-322 operates upstream — at the level of gene transcription — essentially instructing cells to behave as though exercise has occurred. AOD-9604 operates more downstream and tissue-specifically, engaging the machinery of fat breakdown and storage at the adipocyte level. Understanding this fundamental distinction is the starting point for any meaningful comparative research design.

SLU-PP-322: The Exercise Mimetic Research Compound

ERR Agonism and the Transcriptional Exercise Response

SLU-PP-322 was developed as a pan-agonist of the estrogen-related receptor family — specifically ERRα, ERRβ, and ERRγ. These nuclear receptors are master regulators of mitochondrial metabolism, controlling the expression of hundreds of genes involved in oxidative phosphorylation, fatty acid oxidation, and energy substrate utilization. In a resting organism, these pathways are modestly active; during sustained aerobic exercise, ERR activity increases substantially to meet energy demands.

In preclinical mouse models, SLU-PP-322 research has demonstrated increases in running endurance, upregulation of oxidative muscle fibers, and improvements in markers of cardiovascular and metabolic fitness — all without exercise being performed. This makes it a highly novel tool compound for researchers asking fundamental questions about what the “exercise response” actually requires at the molecular level.

Key Findings from Preclinical SLU-PP-322 Studies

Studies in rodent models showed increased treadmill endurance capacity after ERR agonist administration
Skeletal muscle biopsies in treated animals demonstrated upregulation of genes associated with mitochondrial biogenesis (e.g., PGC-1α co-activation targets)
Some models have explored heart failure contexts, where mitochondrial insufficiency is a documented contributor to cardiac decline
Metabolic phenotyping in obese mouse models showed reductions in adiposity and improvements in insulin sensitivity markers
Oxidative fiber type switching (from glycolytic Type II to oxidative Type I) has been observed in several independent datasets

The compound is of particular interest to researchers studying conditions where exercise is physiologically impossible or severely limited — such as degenerative muscle conditions, late-stage heart failure models, or immobility studies.

SLU-PP-322 5MG for laboratory research →

AOD-9604: The Fat-Targeting Growth Hormone Fragment

Origins in Growth Hormone Research

AOD-9604 was originally synthesized as a truncated analog of the C-terminal region of human growth hormone (residues 176–191). Full-length growth hormone has broad anabolic and metabolic effects, including stimulation of IGF-1 production — which complicates its use in targeted fat metabolism research due to the growth-promoting effects of IGF-1. AOD-9604 was specifically engineered to retain the lipolytic properties of growth hormone while removing the IGF-1-stimulating domain.

Preclinical and early clinical research on AOD-9604 proceeded through Phase IIb trials as part of an obesity drug development program, though it did not advance to approval. These trials generated a notable dataset suggesting the compound influenced body composition in human subjects, making it one of the few fat-targeting peptides with any human trial data in the literature — a rarity in the peptide research landscape. For context on peptide regulatory status in 2026, researchers should consult current FDA guidance when planning study protocols.

Adipose Tissue Mechanisms Under Investigation

AOD-9604’s primary area of study involves two interconnected processes in adipose tissue:

Lipolysis stimulation: Research suggests AOD-9604 may activate beta-3 adrenergic pathways in fat cells, triggering the release of stored triglycerides as free fatty acids for oxidation
Lipogenesis inhibition: Separately, studies have explored whether AOD-9604 can reduce the activity of enzymes involved in creating new fat storage, potentially limiting adipogenesis in diet-induced obesity models
Cartilage and tissue repair: Interestingly, a secondary research area has explored AOD-9604’s potential role in cartilage regeneration — the same fat-derived fragment has shown activity in osteoarthritis models, though this remains an early-stage investigation
Non-IGF-1 mechanism: A consistent finding is that AOD-9604’s metabolic effects appear independent of the IGF-1 axis, suggesting a distinct receptor or signaling pathway that remains under active characterization

AOD-9604 10MG for laboratory research →

⚡ UNLOCK 25% OFF YOUR FIRST ORDER

Create a free account — get new-customer pricing on every research peptide, plus new research summaries delivered to your inbox.

For research use only. No spam — unsubscribe anytime.

Head-to-Head Research Comparison

Feature	SLU-PP-322	AOD-9604
Compound class	Small molecule ERR agonist	Growth hormone fragment peptide
Primary mechanism	Nuclear receptor transcription activation	Lipolysis stimulation / lipogenesis inhibition
Primary research target	Mitochondrial biogenesis, exercise adaptation	Adipose tissue metabolism
IGF-1 involvement	Not directly studied	Specifically designed to exclude IGF-1 pathway
Human clinical data	Preclinical only (as of 2026)	Phase IIb trial data available in literature
Secondary research areas	Heart failure, muscle wasting, insulin sensitivity	Cartilage repair, osteoarthritis models
Research context	Exercise science, mitochondrial biology	Obesity pharmacology, adipocyte biology
Receptor target clarity	ERRα/β/γ well characterized	Receptor identity not fully elucidated

Research Design Considerations: Which Compound Fits Which Question?

Choose SLU-PP-322 if…

Your research question centers on mitochondrial function, oxidative capacity, or exercise adaptation at the gene expression level
You are studying muscle physiology in models where exercise cannot be performed (immobility, degenerative conditions)
You are investigating ERR transcription factor biology and its downstream targets
Your model involves heart failure, metabolic syndrome, or conditions where mitochondrial insufficiency is a primary variable
You want to separate the “transcriptional exercise effect” from the physical mechanics of exercise in an experimental design

Choose AOD-9604 if…

Your research centers on adipocyte biology, lipolysis regulation, or fat mass reduction in dietary obesity models
You require a growth hormone-derived compound that does not confound results with IGF-1 signaling
You are building on the existing Phase II clinical literature and want to extend those findings in new preclinical model systems
You are studying dual-pathway obesity interventions where lipogenesis inhibition and lipolysis stimulation are both variables of interest
You have a secondary interest in cartilage or joint tissue research in the same subject population

Parallel Research: Where These Compounds Intersect

While SLU-PP-322 and AOD-9604 operate through distinct pathways, they share a common research universe: the biology of excess adiposity and metabolic dysfunction. SLU-PP-322 addresses fat as an energy substrate problem — the body isn’t burning it efficiently because mitochondrial capacity is insufficient. AOD-9604 addresses fat as a storage problem — the body is accumulating it in adipocytes at rates exceeding breakdown.

Some researchers have speculated that a combinatorial model examining both transcriptional exercise adaptation (via SLU-PP-322) and direct lipolytic stimulation (via AOD-9604) in a diet-induced obesity rodent model could provide a more complete picture of fat mass dynamics than either compound studied alone. This mirrors the approach seen in MOTS-C and NAD+ comparative research, where overlapping but mechanistically distinct mitochondrial compounds are evaluated side by side to map the full landscape of metabolic regulation.

Additionally, MOTS-C’s role in mitochondrial signaling offers another parallel for researchers building multi-compound metabolic panels, as all three compounds — SLU-PP-322, AOD-9604, and MOTS-C — engage metabolic dysfunction from unique angles.

For researchers whose interest extends to the GLP axis in the same metabolic models, GLP-1, GLP-2, and GLP-3 research provides a receptor-level complement to the intracellular approaches represented by SLU-PP-322 and AOD-9604.

Current Research Landscape in 2026

SLU-PP-322 is an emerging tool compound — most of the published work comes from the Washington University group that originally synthesized it, and the compound is beginning to attract broader laboratory interest. AOD-9604, by contrast, has a longer research trail, including human trial data from early 2000s pharmaceutical development programs, making it one of the more characterized peptides in the metabolic fat research category despite never achieving regulatory approval.

Both compounds have drawn renewed interest in 2026 as the limitations of current GLP-1-class approaches become more apparent in research contexts — particularly in areas like muscle preservation (where GLP-1 agonists may promote lean mass loss alongside fat loss) and direct adipocyte biology. Compounds that engage fat metabolism through entirely different mechanisms offer researchers tools to dissect which components of metabolic intervention are driving observed effects.

GLP-1 (S) 10MG Nasal Spray for complementary metabolic research →

MOTS-C 10MG Nasal Spray for mitochondrial metabolic studies →

Where These Fit in Your Research Library

Researchers building metabolic peptide panels in 2026 may find these two compounds serve as non-overlapping mechanistic anchors — one for transcriptional/mitochondrial work, one for adipocyte-specific lipolytic work. Both are available in research-grade formulations for laboratory acquisition.

Final Takeaway: Mapping Metabolic Mechanisms Requires the Right Tool for Each Question

SLU-PP-322 and AOD-9604 are not interchangeable research compounds — they are purpose-built tools for distinct questions in metabolic biology. SLU-PP-322 is the instrument of choice when the research question is about exercise adaptation, mitochondrial activation, or oxidative capacity at the gene expression level. AOD-9604 is the instrument of choice when the question concerns adipocyte-level fat breakdown, storage inhibition, or the specific lipolytic properties of growth hormone in the absence of IGF-1 signaling.

For metabolic researchers in 2026 looking to build comprehensive experimental frameworks, understanding where each compound’s mechanism begins and ends is the foundation of sound study design. These two peptides together illustrate how varied and layered the biology of metabolic dysfunction truly is — and why single-pathway approaches rarely capture the full picture in preclinical research.

Sources & Further Reading

Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.